[Close]
- This page was created by volunteers like you!
- Help us make it even better. To learn more about contributing to MEpedia, click here.
- Join the movement
- Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
- Congratulations!
- MEpedia has got over 30 million views as of August 2022!
Famotidine
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Famotidine is a non-sedating antihistamine that blocks the H2 histamine receptor. Famotidine is available over the counter and on perscription and is used to treat and prevent ulcers, gastroesophageal reflux disease (GERD) and other conditions that cause heartburn.[1]
Famotidine brand names include Pepcid and Zantac 360 (not to be confused with Zantac, which contains different active ingredients).[1][2][3]
Theory[edit | edit source]
Evidence[edit | edit source]
Long COVID[edit | edit source]
Famotidine has limited evidence for use in Long COVID patients from a small observational study by Glynne et al. (2022), in which H1 and H2 blockers were used together.[4]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Available over the counter or on perscription.[1][3][2]
Notable studies[edit | edit source]
- 2022, Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines[4] - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Famotidine - DrugBank Online
- Famotidine - drugs.com
- Famotidine - WebMD
References[edit | edit source]
- ↑ Jump up to: 1.0 1.1 1.2 "Famotidine Uses, Dosage & Side Effects". Drugs.com. Retrieved February 19, 2022.
- ↑ Jump up to: 2.0 2.1 "Famotidine - Uses, Side Effects, and More". WebMD. Retrieved February 19, 2022.
- ↑ Jump up to: 3.0 3.1 "Famotidine: Uses, Interactions, Mechanism of Action". Drugbank Online. Retrieved February 19, 2022.
- ↑ Jump up to: 4.0 4.1 Glynne, Paul; Tahmasebi, Natasha; Gant, Vanya; Gupta, Rajeev (January 2022). "Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines". Journal of Investigative Medicine. 70 (1): 61–67. doi:10.1136/jim-2021-002051. ISSN 1081-5589. PMC 8494538. PMID 34611034.
